1q Gain FISH : 1015905

Test Code
MDFCP1QGF or 1015905

CPT Codes
88271, 88275

Instructions
Bone Marrow aspirate in a green top sodium heparin tube (2-3 mL) or Peripheral Blood in a green top sodium heparin tube (2-10 mL).

Transport Container
Blood or Bone Marrow: Do not centrifuge.

Transport Temperature
Blood or Bone Marrow: Ambient temperature within 24 hours. Specimen can be refrigerated if not transported immediately. Do not freeze. Protect from heat with a cold pack.

Specimen Stability
Blood and Bone Marrow: Ambient: 48 hours; Refrigerated: 48 hours; Frozen: Unacceptable

Methodology
Fluorescence in situ hybridization (FISH)

Setup Schedule
Monday - Friday

Report Available
Up to 10 days

Limitations
Laboratory test results should always be considered in the context of clinical observations. This test was developed and its performance characteristics determined by med fusion. It has not been cleared or approved by the U.S. Food and Drug Administration
(FDA). The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments
of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing.

Reference Range
An interpretive report will be provided.

med fusion can deliver your FISH report by fax or eLabs Results Portal. Please contact your medfusion representative to make them aware of your desired delivery and if you need access to the results portal. The results portal will provide links for additional therapy and clinical trial information associated with the patient’s molecular profile.
If you have any further questions, additional needs and would like to speak with med fusion’s scientific staff, pathologists, or client services please contact us at 972-966-7050/844-966-7050.

Clinical Significance
Myeloma is a malignant proliferation of monoclonal plasma cells. Although morphologically similar, several genetic subtypes have been identified by molecular and genetic profiling. These subtypes are associated with unique clinico-pathological features and dissimilar outcome. In addition to other genetic aberrations, Chromosome 1 abnormalities (gain of 1q and loss of 1p) are commonly reported as recurrent abnormalities in myeloma cases. Abnormalities of chromosome 1 (gain of 1q and loss of 1p) are considered as secondary abnormalities acquired during clonal evolution1 and are regarded as poor prognostic markers associated with shorter survival and adverse outcome in plasma cell myeloma cases1,2.
1) HematolOncolClinNorth Am. 2007 Dec;21(6):1115-40.Prognostic factors and staging in multiple myeloma. Fonseca R,San Miguel J.
2) Leukemia. 2009 Dec;23(12):2210-21. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

Performing Laboratory
med fusion



The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed. Any Profile/panel component may be ordered separately. Reflex tests are performed at an additional charge.